Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHI-921 is a standardized cannabis extract in sunflower oil developed by Canopy Growth for the treatment of insomnia. It is classified as a herbal medicine that was being investigated for its potential to improve sleep initiation and maintenance in patients with insomnia. The development program included a Phase 2 clinical trial (identified as H2017-01) that was ultimately terminated in June 2020. According to the search results, the drug's development has been discontinued, and it did not receive regulatory approval. The product was formulated as a standardized cannabis extract in sunflower oil and was administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standardized cannabis extract in sunflower oil.